Harbin Medisan Pharmaceutical Dividends and Buybacks
Dividend criteria checks 1/6
Harbin Medisan Pharmaceutical is a dividend paying company with a current yield of 1.96%.
Key information
2.0%
Dividend yield
0.04%
Buyback Yield
Total Shareholder Yield | 2.0% |
Future Dividend Yield | n/a |
Dividend Growth | -3.1% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | CN¥0.200 |
Payout ratio | 112% |
Recent dividend and buyback updates
Recent updates
Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Shares Climb 25% But Its Business Is Yet to Catch Up
Nov 11Harbin Medisan Pharmaceutical (SZSE:002900) Posted Weak Earnings But There Is More To Worry About
Sep 05Harbin Medisan Pharmaceutical (SZSE:002900) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jun 01Is Harbin Medisan Pharmaceutical (SZSE:002900) A Risky Investment?
May 23Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Mar 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 002900 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 002900 has only been paying a dividend for 6 years, and since then payments have fallen.
Dividend Yield vs Market
Harbin Medisan Pharmaceutical Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (002900) | 2.0% |
Market Bottom 25% (CN) | 0.5% |
Market Top 25% (CN) | 2.1% |
Industry Average (Pharmaceuticals) | 1.7% |
Analyst forecast (002900) (up to 3 years) | n/a |
Notable Dividend: 002900's dividend (1.96%) is higher than the bottom 25% of dividend payers in the CN market (0.53%).
High Dividend: 002900's dividend (1.96%) is low compared to the top 25% of dividend payers in the CN market (2.08%).
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (112.2%), 002900's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: 002900 is paying a dividend but the company has no free cash flows.